

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Baijin Life Science Holdings Limited

佰金生命科學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1466)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION FRAMEWORK AGREEMENT

This is a voluntary announcement made by Baijin Life Science Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the Shareholders and potential investors of the Company that, Beijing Baijin Biotechnology Company Limited (“**Beijing Baijin**”) (北京佰金生物科技有限公司), an indirect wholly-owned subsidiary of the Company, has entered into a strategic cooperation framework agreement (the “**Cooperation Framework Agreement**”) with Foryoung Biotechnology Co., Ltd.* (“**Foryoung Biotechnology**”) (扶搖元氣生物科技有限公司) in relation to strategic cooperation in the field of clinical cell therapy.

Pursuant to the Cooperation Framework Agreement, Beijing Baijin shall be responsible for the research and development, production, quality control and global supply chain support of the products within the scope of cooperation, and shall establish a unified compliance standards system. Foryoung Biotechnology shall leverage its expert team, patent portfolio and market operation capabilities to facilitate the direct integration of Beijing Baijin’s technical production capacity with Foryoung Biotechnology’s technological capabilities, thereby completing the clinical translation loop from “capability” to “implementation”.

Foryoung Biotechnology’s core technologies are derived from the commercialisation of scientific research achievements of leading higher education and research institutions in the PRC. It has entered into specialised technology transfer cooperation arrangements and obtained exclusive authorisation in respect of the relevant patents. Foryoung Biotechnology also has experience in filings relating to clinical cell drug research.

The Board believes that such cooperation is expected to enable consumers to make more informed decisions when selecting cell-related products and services by reference to clearer qualification and certification standards, thereby reducing the risk of blind trial-and-error in the market. The Board further notes that, with the “Regulations on the Administration of Clinical Research and Clinical Translation Application of New Biomedical Technologies”(《生物醫學新技術臨床研究和臨床轉化應用管理條例》) (State Council Order

No. 818) coming into effect on 1 May 2026, the domestic cell industry is expected to enter a more regulated stage, moving away from the previous market environment characterised by “concept-driven development ahead of standards”. The Board considers that enterprises lacking technological validation and clinical filing qualifications may face increasing market pressure, whereas enterprises with accumulated technologies, patent deployment and clinical research capabilities may be better positioned to advance from technological development to industrial application.

The Board wishes to emphasise that the Cooperation Framework Agreement only sets out the preliminary cooperation intentions of Beijing Baijin and Foryoung Biotechnology, which does not constitute any substantive right and obligation of any parties thereto and is subject to further formal agreement(s) and/or arrangement(s) to be entered into by the parties, which may or may not materialise. Where necessary, further announcement(s) will be made by the Company as and when appropriate in compliance with the relevant Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, Foryoung Biotechnology and its ultimate beneficial owners are third parties independent of and not connected with the Company and its connected persons as defined in the relevant Listing Rules.

The Board wishes to emphasise that a definitive agreement may or may not be entered into by the parties and as such the cooperation with Foryoung Biotechnology may or may not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
BAIJIN LIFE SCIENCE HOLDINGS LIMITED
Cheung Sze Ming
Executive Director

Hong Kong, 6 May 2026

As at the date of this announcement, the Board comprises Mr. Cheung Sze Ming, Mr. Dong Peng and Dr. Su Yaoyao as executive Directors; Mr. Zhu Yongjun, Mr. Cheng Chi Kin and Ms. Xie Chunchen as non-executive Directors; Mr. Wong Siu Keung Joe, Mr. Chang Chunyu and Ms. Shen Ding as independent non-executive Directors.

* *For identification purposes only*